Marinus Pharmaceuticals
Marinus Pharmaceuticals Cuts 45% of Workforce Following Clinical Setbacks
Marinus Pharmaceuticals, layoffs, workforce reduction, clinical setbacks, ganaxolone, seizures, tuberous sclerosis complex (TSC), refractory status epilepticus (RSE)
Marinus Pharmaceuticals Slashes 45% of Workforce Following Disappointing Phase 3 Trial Results
Marinus Pharmaceuticals, staff layoffs, phase 3 trials, ganaxolone, refractory status epilepticus, RAISE trial, TrustTSC trial
Marinus Pharmaceuticals to Reduce Workforce and Explore Strategic Alternatives Following Disappointing Trial Results
Marinus Pharmaceuticals, workforce reduction, strategic alternatives, Ztalmy trial, pharmaceutical industry, biotech layoffs
Marinus Pharmaceuticals Reduces Workforce Amidst Challenges in Epilepsy Treatment Development
Marinus Pharmaceuticals, workforce reduction, epilepsy treatment, clinical trials, financial restructuring